Chidamide synergizes with cisplatin-etoposide to trigger pyroptosis and anti-tumor immunity in diffuse large B-cell lymphoma
Combining an older drug class with standard chemotherapy triggers cancer cell death and awakens immune cells against lymphoma in lab models, pointing toward a testable combination strategy.
The HDAC inhibitor chidamide synergizes with cisplatin and etoposide to trigger gasdermin E-dependent pyroptosis in DLBCL models, remodeling the tumor microenvironment through increased dendritic cell, NK cell, and CD8+ T cell infiltration. CD8+ T cell depletion abolishes the therapeutic effect, confirming immunogenic cell death as the primary mechanism of this combination.
What the study was
- Study design
- Preclinical (cell lines + syngeneic mouse model)
- Population
- DLBCL cell lines and syngeneic mouse models
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Communications Medicine
Why it surfaced
Novel immunogenic pyroptosis mechanism in DLBCL preclinically; chidamide already approved in China; combination warrants clinical investigation but capped at 5 for preclinical data only.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.